Background: This study assessed the effectiveness of Yang Xin Tang in the treatment of coronary heart disease patients with angina pectoris.
Methods: In this study, we systematically and comprehensively searched the PUBMED, EMBASE, Cochrane Library, CNKI, WANGFANG, and VIP databases from their establishment to June 1, 2022. Clinical randomized controlled trials of Yang Xin Tang for the management of angina pectoris in patients with coronary heart disease were considered for inclusion. The outcomes included the response rate of angina pectoris, response rate based on electrocardiogram, and the rate of nitroglycerin use. Two authors independently performed literature selection, data extraction, and methodological quality assessment. Any differences were resolved by a third author through a discussion.
Results: Nine trials involving 819 patients were included. The meta-analysis results showed that Yang Xin Tang significantly improved the response rate of angina pectoris (OR = 2.98, 95% CI: 1.96-4.55, I2 = 0%, P < .01) and the response rate based on the electrocardiogram (OR = 1.88, 95% CI: 1.28-2.78, I2 = 26%, P < .01), and significantly reduced the rate of nitroglycerin use (OR = 2.04, 95% CI: 1.19-3.52, I2 = 0%, P = .01).
Conclusions: The results of this study showed that Yang Xin Tang was effective in the treatment of patients with angina pectoris of coronary heart disease. Further studies are required to confirm these results.